Cost of recurrence among patients with HR+/HER2-metastatic breast cancer.

被引：0
|
作者：
Engel-Nitz, Nicole M.
Becker, Laura
Gerdes, Randall
Hao, Yanni
机构：
[1] Optum, Eden Prairie, MN USA
[2] Novartis Pharmaceut, E Hanover, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e11504
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11504
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Clinical outcomes among HR+/HER2-metastatic breast cancer patients with multiple metastatic sites
    Xie, J.
    Hao, Y.
    Li, N.
    Lin, P. L.
    Ohashi, E.
    Koo, V.
    Wu, E. Q.
    CANCER RESEARCH, 2016, 76
  • [2] Abemaciclib in HR+/HER2-metastatic breast cancer: A realworld experience
    Bottosso, M.
    Giarratano, T.
    Barbieri, C.
    Menichetti, A.
    Cumerlato, E.
    Miglietta, F.
    Genovesi, E.
    Amato, O.
    Dieci, M. V.
    Griguolo, G.
    Guarneri, V.
    ANNALS OF ONCOLOGY, 2021, 32 : S73 - S74
  • [3] Validation of Claims Algorithm to Identify HR+/HER2-Metastatic Breast Cancer Patients
    Chin, Andi
    Wu, Xiyuan
    Ip, Queeny
    Lyle, Derek
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 620 - 620
  • [4] Economic Burden of HR+/HER2-Metastatic Breast Cancer Among Adult Premenopausal Women
    Gauthier, Genevieve
    Gagnon-Sanschagrin, Patrick
    Guerin, Annie
    Burne, Rebecca
    Small, Tania
    Niravath, Polly
    Dalal, Anand A.
    ADVANCES IN THERAPY, 2018, 35 (04) : 503 - 514
  • [5] Treatment patterns and resource utilization among elderly Medicare patients with HR+/HER2-metastatic breast cancer
    Goyal, R. K.
    Carter, G. C.
    Nagar, S. N.
    Smyth, E. N.
    Price, G. L.
    Huang, Y-J
    Bromund, J. L.
    Li, L.
    Schilder, J. M.
    Davis, K. L.
    Kaye, J. A.
    CANCER RESEARCH, 2017, 77
  • [6] Experience with eribulin in HR+/HER2-metastatic breast cancer, including a male
    Munoz Sanchez, Maria del Mar
    Soriano Rodriguez, Maria del Carmen
    Molina Garrido, Maria Jose
    Lopez-Gonzalez, Ana
    Garcia-Palomo, Andres
    Lopez-Gonzalez, Laura
    Plata Fernandez, Maria Yessica
    Luque Caro, Natalia
    Sanchez Rovira, Pedro
    FUTURE ONCOLOGY, 2018, 14 (07) : 5 - 12
  • [7] Sacituzumab govitecan in HR+ and HER2-metastatic breast cancer: for all or for some?
    Loibl, Sibylle
    Holtschmidt, Johannes
    LANCET, 2023, 402 (10411): : 1394 - 1395
  • [8] Physician survey in the treatment of HR+/HER2-metastatic breast cancer in Egypt
    Aboelkheir, E.
    Ashour, A.
    Fadel, S.
    Arafat, W.
    BREAST, 2021, 56 : S31 - S31
  • [9] Efficacy and safety of palbociclib in heavily pretreated patients with HR+/HER2-metastatic breast cancer
    Ban, Marija
    Mise, Branka Petric
    Majic, Ana
    Drazic, Ivanka
    Vrdoljak, Eduard
    FUTURE ONCOLOGY, 2018, 14 (06) : 537 - 544
  • [10] VALIDATION OF AN ALGORITHM TO IDENTIFY HR+/HER2-METASTATIC BREAST CANCER IN CLAIMS DATA
    Chin, A.
    Ip, Q.
    Wu, X.
    Lyle, D.
    VALUE IN HEALTH, 2024, 27 (06) : S163 - S163
12345